Literature DB >> 10801912

Antagonism of arachidonic acid is linked to the antitumorigenic effect of dietary eicosapentaenoic acid in Apc(Min/+) mice.

M B Petrik1, M F McEntee, C H Chiu, J Whelan.   

Abstract

The multiple intestinal neoplasia (Apc(Min/+)) mouse possesses a germline mutation at codon 850 of the adenomatous polyposis coli (Apc) gene resulting in the formation of a nonfunctional truncated gene product. Following a somatic mutation of the remaining wild-type allele, mice spontaneously develop approximately 40-50 tumors throughout the intestinal tract. This mouse model has been used to study intestinal tumorigenesis because this mutation is analogous to the inherited APC mutation in humans with familial adenomatous polyposis (FAP). These individuals characteristically develop numerous adenomas throughout their intestinal tracts. Only a few studies have evaluated the effects of dietary fatty acids on tumorigenesis in this animal model with varying results, and none have linked these effects to alterations in arachidonic acid (AA) metabolism. This study was designed to evaluate the antitumorigenic effect of dietary (n-3) polyunsaturated fatty acids (PUFA) in the Apc(Min/+) mouse model and to determine whether these effects are related to inhibition of AA metabolism. Male Apc(Min/+)mice were fed diets supplemented with eicosapentaenoic acid (EPA), AA or a combination of AA + EPA. Mean tumor number in the EPA group was 68% lower (P<0.05) compared with the control group, whereas AA supplementation did not significantly alter tumor load. The reduction in tumor load coincided with significant reductions in intestinal AA content and levels of prostaglandins. However, supplementing AA to the EPA diet (AA + EPA) abolished the antitumorigenic effect of EPA, increased tissue AA content fourfold and prostaglandin production two- to fourfold. These results indicate that AA is involved in tumorigenesis and suggest that EPA's ability to reduce tumor load in Apc(Min/+) mice is related to reductions in tissue AA content or its metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10801912     DOI: 10.1093/jn/130.5.1153

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  17 in total

1.  Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis.

Authors:  K H Hong; J C Bonventre; E O'Leary; J V Bonventre; E S Lander
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 2.  Chemoprevention in familial adenomatous polyposis.

Authors:  Brian Kim; Francis M Giardiello
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

3.  Dietary intake of PUFAs and colorectal polyp risk.

Authors:  Harvey J Murff; Martha J Shrubsole; Qiuyin Cai; Walter E Smalley; Qi Dai; Ginger L Milne; Reid M Ness; Wei Zheng
Journal:  Am J Clin Nutr       Date:  2012-01-25       Impact factor: 7.045

Review 4.  Prostaglandin E3 metabolism and cancer.

Authors:  Peiying Yang; Yan Jiang; Susan M Fischer
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

5.  Dietary omega-3-polyunsaturated fatty acids prevent the development of metastases of colon carcinoma in rat liver.

Authors:  Carsten N Gutt; Lars Brinkmann; Arianeb Mehrabi; Hamidreza Fonouni; Beat P Müller-Stich; Gregor Vetter; Jürgen M Stein; Peter Schemmer; Markus W Büchler
Journal:  Eur J Nutr       Date:  2007-06-25       Impact factor: 5.614

6.  Comparison of the effects of dietary alpha-linolenic, stearidonic, and eicosapentaenoic acids on production of inflammatory mediators in mice.

Authors:  Kenji Ishihara; Wataru Komatsu; Hiroaki Saito; Kazuki Shinohara
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

7.  Is the omega-3 index a valid marker of intestinal membrane phospholipid EPA+DHA content?

Authors:  Eric A Gurzell; Jason A Wiesinger; Christina Morkam; Sophia Hemmrich; William S Harris; Jenifer I Fenton
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-04-24       Impact factor: 4.006

8.  Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer.

Authors:  Michael F McEntee; Carol Ziegler; Danielle Reel; Kenneth Tomer; Ahmed Shoieb; Mark Ray; Xiaoou Li; Nancy Neilsen; Fred B Lih; Dorcas O'Rourke; Jay Whelan
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

9.  The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility.

Authors:  G Hawcroft; M Volpato; G Marston; N Ingram; S L Perry; A J Cockbain; A D Race; A Munarini; A Belluzzi; P M Loadman; P L Coletta; M A Hull
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

10.  n3 and n6 polyunsaturated fatty acids differentially modulate prostaglandin E secretion but not markers of lipogenesis in adipocytes.

Authors:  Patrick Wortman; Yuko Miyazaki; Nishan S Kalupahana; Suyeon Kim; Melissa Hansen-Petrik; Arnold M Saxton; Kate J Claycombe; Brynn H Voy; Jay Whelan; Naima Moustaid-Moussa
Journal:  Nutr Metab (Lond)       Date:  2009-01-21       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.